Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Net operating profit after taxes (NOPAT)1 | 2,392,410) | 1,778,708) | (4,619,749) | 1,185,025) | 1,018,004) | 771,526) | |
| Invested capital2 | 13,020,519) | 12,902,673) | 7,128,161) | 12,346,959) | 12,285,847) | 10,870,238) | |
| Performance Ratio | |||||||
| ROIC3 | 18.37% | 13.79% | -64.81% | 9.60% | 8.29% | 7.10% | |
| Benchmarks | |||||||
| ROIC, Competitors4 | |||||||
| Abbott Laboratories | 10.96% | 11.30% | — | — | — | — | |
| Elevance Health Inc. | 10.24% | 11.26% | — | — | — | — | |
| Intuitive Surgical Inc. | 22.01% | 37.63% | — | — | — | — | |
| Medtronic PLC | 7.02% | 5.59% | — | — | — | — | |
| UnitedHealth Group Inc. | 13.68% | 13.51% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 NOPAT. See details »
2 Invested capital. See details »
3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 2,392,410 ÷ 13,020,519 = 18.37%
4 Click competitor name to see calculations.
The financial performance from 2017 to 2022 is characterized by a period of steady growth, a severe operational disruption in 2020, and a robust subsequent recovery that resulted in significantly higher capital efficiency.
- Net Operating Profit After Taxes (NOPAT) Trends
- Profitability exhibited a consistent upward trend between 2017 and 2019, rising from 771.5 million to 1.19 billion. This growth was interrupted by a substantial loss in 2020, where NOPAT fell to negative 4.62 billion. A strong recovery followed, with NOPAT increasing to 1.78 billion in 2021 and further expanding to 2.39 billion by 2022, surpassing pre-disruption levels.
- Invested Capital Fluctuations
- Invested capital grew steadily from 10.87 billion in 2017 to 12.35 billion in 2019. A significant contraction occurred in 2020, with capital dropping to 7.13 billion. This figure rebounded sharply in 2021 to 12.90 billion and remained stable at 13.02 billion in 2022, suggesting a restoration and slight expansion of the capital base.
- Return on Invested Capital (ROIC) Analysis
- The ROIC demonstrated steady improvement from 7.10% in 2017 to 9.60% in 2019. The extreme volatility of 2020 led to a sharp decline to -64.81%. However, the period following 2020 showed an accelerated improvement in capital efficiency, with ROIC climbing to 13.79% in 2021 and reaching 18.37% in 2022. This trajectory indicates that the company achieved a significantly higher rate of return on its deployed capital by the end of the analyzed period than at its inception.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The return on invested capital (ROIC) exhibited significant volatility between 2017 and 2022, characterized by a period of steady growth, a severe contraction in 2020, and a subsequent strong recovery.
- Operating Profit Margin (OPM)
- Margins remained lean throughout the period, generally fluctuating around 1%. A notable anomaly occurred in 2020, where the margin dropped to -2.60%, indicating an operating loss. Following this decline, the margin recovered to 1.01% in 2021 and reached a period high of 1.16% by September 30, 2022.
- Turnover of Capital (TO)
- Capital efficiency showed a sharp increase over time. While the turnover ratio remained relatively stable between 13.67 and 14.55 from 2017 to 2019, it spiked to 26.64 in 2020. Post-2020, the ratio stabilized at a higher plateau than the pre-2020 levels, ending at 18.32 in 2022, which suggests a more efficient utilization of invested capital to generate revenue.
- Effective Cash Tax Rate Impact
- The factor representing the portion of profits retained after taxes (1 – CTR) fluctuated between 71.60% and 100.00%. The peak of 100.00% in 2020 coincides with the operating loss, as no cash taxes were paid. In the final two years, the retention rate remained high, ending at 86.56% in 2022.
- Return on Invested Capital (ROIC) Synthesis
- The ROIC trend was driven primarily by the interaction between operating margins and capital turnover. Steady growth was observed from 2017 (7.10%) to 2019 (9.60%). The extreme decline to -64.81% in 2020 was a direct result of the negative operating profit margin, which outweighed the benefit of an exceptionally high capital turnover. The subsequent recovery to 18.37% in 2022 was fueled by the dual impact of expanding operating margins and a sustained increase in capital turnover efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin (OPM)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Net operating profit after taxes (NOPAT)1 | 2,392,410) | 1,778,708) | (4,619,749) | 1,185,025) | 1,018,004) | 771,526) | |
| Add: Cash operating taxes2 | 371,488) | 385,676) | (316,612) | 121,219) | 403,869) | 288,588) | |
| Net operating profit before taxes (NOPBT) | 2,763,899) | 2,164,384) | (4,936,361) | 1,306,244) | 1,421,873) | 1,060,114) | |
| Revenue | 238,587,006) | 213,988,843) | 189,893,926) | 179,589,121) | 167,939,635) | 153,143,826) | |
| Profitability Ratio | |||||||
| OPM3 | 1.16% | 1.01% | -2.60% | 0.73% | 0.85% | 0.69% | |
| Benchmarks | |||||||
| OPM, Competitors4 | |||||||
| Abbott Laboratories | 20.24% | 20.37% | — | — | — | — | |
| Elevance Health Inc. | 5.64% | 6.58% | — | — | — | — | |
| Intuitive Surgical Inc. | 26.19% | 33.56% | — | — | — | — | |
| Medtronic PLC | 19.15% | 16.48% | — | — | — | — | |
| UnitedHealth Group Inc. | 9.13% | 8.33% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
OPM = 100 × NOPBT ÷ Revenue
= 100 × 2,763,899 ÷ 238,587,006 = 1.16%
4 Click competitor name to see calculations.
The financial trajectory between 2017 and 2022 is characterized by consistent top-line expansion contrasted with significant volatility in operating profitability. While revenue demonstrated a steady upward trend, the net operating profit before taxes (NOPBT) and the resulting operating profit margin (OPM) experienced a severe contraction in 2020 before recovering to levels that exceeded pre-anomaly peaks.
- Revenue Growth Trends
- A consistent increase in revenue is observed throughout the period, rising from 153.14 billion USD in 2017 to 238.59 billion USD in 2022. This steady growth indicates a continuous expansion of the company's operational scale and market reach over the six-year span.
- Operating Profitability and Margin Analysis
- Operating profit margins remained lean, which is characteristic of the sector's business model. Between 2017 and 2019, the OPM fluctuated within a narrow range of 0.69% to 0.85%. Following a sharp decline in 2020, the margin recovered to 1.01% in 2021 and reached a period high of 1.16% by 2022, suggesting an improvement in operational efficiency and cost management in the final two years of the analysis.
- Analysis of the 2020 Performance Anomaly
- A significant divergence between revenue and profit occurred in 2020. Despite revenue continuing to grow to 189.89 billion USD, NOPBT fell sharply to negative 4.94 billion USD, causing the OPM to drop to -2.60%. This anomaly represents a substantial deviation from the otherwise positive trend of the period.
- Recovery and Profitability Expansion
- The period from 2021 to 2022 is marked by a strong recovery. NOPBT rose from its 2020 low to 2.16 billion USD in 2021 and further expanded to 2.76 billion USD in 2022. This recovery not only offset the 2020 losses but also elevated the absolute operating profit and the profit margin beyond the levels recorded between 2017 and 2019.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Turnover of Capital (TO)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Revenue | 238,587,006) | 213,988,843) | 189,893,926) | 179,589,121) | 167,939,635) | 153,143,826) | |
| Invested capital1 | 13,020,519) | 12,902,673) | 7,128,161) | 12,346,959) | 12,285,847) | 10,870,238) | |
| Efficiency Ratio | |||||||
| TO2 | 18.32 | 16.58 | 26.64 | 14.55 | 13.67 | 14.09 | |
| Benchmarks | |||||||
| TO, Competitors3 | |||||||
| Abbott Laboratories | 0.71 | 0.69 | — | — | — | — | |
| Elevance Health Inc. | 2.33 | 2.14 | — | — | — | — | |
| Intuitive Surgical Inc. | 1.16 | 1.27 | — | — | — | — | |
| Medtronic PLC | 0.46 | 0.42 | — | — | — | — | |
| UnitedHealth Group Inc. | 1.95 | 2.04 | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 Invested capital. See details »
2 2022 Calculation
TO = Revenue ÷ Invested capital
= 238,587,006 ÷ 13,020,519 = 18.32
3 Click competitor name to see calculations.
The financial performance from 2017 to 2022 is characterized by consistent revenue expansion and a general increase in capital utilization efficiency, punctuated by a significant structural shift in the invested capital base during the 2020 fiscal year.
- Revenue Growth Trends
- A sustained upward trajectory in revenue is observed, increasing from US$ 153.1 billion in 2017 to US$ 238.6 billion in 2022. This growth reflects a steady expansion of operational scale over the six-year period.
- Invested Capital Dynamics
- Invested capital remained relatively stable between 2017 and 2019, ranging from US$ 10.9 billion to US$ 12.3 billion. A substantial contraction occurred in 2020, with invested capital dropping to US$ 7.1 billion. This was followed by a return to previous levels, reaching US$ 13.0 billion by 2022.
- Turnover of Capital (TO) Analysis
- The turnover of capital ratio indicates a general improvement in asset productivity, rising from 14.09 in 2017 to 18.32 in 2022. An exceptional spike to 26.64 is noted in 2020, which is directly attributable to the sharp decline in the invested capital denominator rather than an anomalous surge in revenue. In the subsequent years, as invested capital normalized, the turnover ratio remained higher than the 2017-2019 average, suggesting an increase in the efficiency with which the organization generates revenue from its capital base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Effective Cash Tax Rate (CTR)
| Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | ||
|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||
| Net operating profit after taxes (NOPAT)1 | 2,392,410) | 1,778,708) | (4,619,749) | 1,185,025) | 1,018,004) | 771,526) | |
| Add: Cash operating taxes2 | 371,488) | 385,676) | (316,612) | 121,219) | 403,869) | 288,588) | |
| Net operating profit before taxes (NOPBT) | 2,763,899) | 2,164,384) | (4,936,361) | 1,306,244) | 1,421,873) | 1,060,114) | |
| Tax Rate | |||||||
| CTR3 | 13.44% | 17.82% | — | 9.28% | 28.40% | 27.22% | |
| Benchmarks | |||||||
| CTR, Competitors4 | |||||||
| Abbott Laboratories | 23.97% | 20.05% | — | — | — | — | |
| Elevance Health Inc. | 22.01% | 20.22% | — | — | — | — | |
| Intuitive Surgical Inc. | 27.40% | 11.76% | — | — | — | — | |
| Medtronic PLC | 19.53% | 18.59% | — | — | — | — | |
| UnitedHealth Group Inc. | 23.25% | 20.32% | — | — | — | — | |
Based on: 10-K (reporting date: 2022-09-30), 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 371,488 ÷ 2,763,899 = 13.44%
4 Click competitor name to see calculations.
The effective cash tax rate (CTR) exhibits significant volatility between 2017 and 2022, characterized by a marked departure from initial levels and a period of extreme financial instability in 2020.
- Cash Tax Rate Trends
- Between 2017 and 2018, the CTR remained relatively stable and elevated, ranging from 27.22% to 28.40%. A sharp decline occurred in 2019, with the rate dropping to 9.28%. Following a period of non-calculability in 2020, the rate recovered to 17.82% in 2021 before trending downward again to 13.44% in 2022.
- Operating Profit and Tax Correlation
- A critical anomaly is observed in 2020, where net operating profit before taxes (NOPBT) fell to a deficit of 4.94 billion US$. This coincided with negative cash operating taxes of 316.61 million US$, representing a cash tax benefit or refund. This inverse relationship underscores a period of severe operational distress that disrupted the standard tax rate trajectory.
- Post-Recovery Tax Efficiency
- In the period following the 2020 loss, NOPBT grew substantially, reaching 2.76 billion US$ by 2022. Despite this increase in profitability, the CTR remained significantly lower than the 2017-2018 baseline. The reduction to 13.44% in 2022, while profits were at a six-year high, suggests a possible utilization of tax loss carry-forwards from the 2020 deficit or other structural tax efficiencies.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?